Latest news on the vaccine and the Delta variant – .

0
22
Canada Extends Covid-19 Travel Restrictions With United States Until July 21 – .


A nurse prepares the Pfizer Covid-19 vaccine, a social housing project pop-up site targeting vulnerable communities in Los Angeles, Calif., March 10. Frederic J. Brown / AFP / Getty Images

Pfizer said Thursday it is seeing a decrease in immunity from its coronavirus vaccine and is redoubling its efforts to develop a booster dose that will protect people from the variants.

“As real-world data released by the Israeli Ministry of Health shows, the vaccine’s effectiveness in preventing both infection and symptomatic disease decreased six months after vaccination, although the effectiveness in the prevention of serious illness remains high, ”the company said in a statement sent to CNN.

“In addition, during this period, the Delta variant becomes the dominant variant in Israel as well as in many other countries. These results are consistent with an ongoing analysis of the phase 3 study of the companies, ”he added.

“While protection against serious illness has remained high for the full six months, a decline in efficacy against symptomatic illness over time and the continued emergence of variants are expected. Based on all of the data available to them to date, Pfizer and BioNTech believe that a third dose may be beneficial within 6 to 12 months of the second dose to maintain the highest levels of protection.

A spokesperson for Pfizer later told CNN that the company plans to file an emergency use authorization application for a booster dose with the United States Food and Drug Administration in August.

Israel’s health ministry said in a statement earlier this week that it had seen the efficacy of Pfizer’s vaccine drop from more than 90% to around 64% as variant B.1.617.2 or Delta worsened. propagated.

The company said booster doses of its vaccine, developed with BioNTech, produce levels of neutralizing antibodies five to ten times higher than those produced after two doses.

“The companies plan to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks,” said Pfizer in a statement.

And he says he’s also developing a new formulation for a booster dose that might better protect people from the newer variants.

“While Pfizer and BioNTech believe that a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants, including Delta, the companies remain vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine. which targets the complete spike protein of the Delta variant, ”the company said. Current vaccines target only part of the spike protein – the part of the virus that it uses to attach to cells.

“The first batch of mRNA for the assay has already been manufactured at BioNTech’s facilities in Mainz, Germany. The companies expect clinical studies to begin in August, subject to regulatory approvals. “

LEAVE A REPLY

Please enter your comment!
Please enter your name here